PURPOSE: Survivin (BIRC5) is a promising tumor biomarker. Conflicting data exist on its prognostic effect in breast cancer. These data may at least be partly due to the manual interpretation of immunohistochemical staining, especially as survivin can be located in both the nucleus and cytoplasm. Quantitative determination of survivin expression using image analysis offers the opportunity to develop alternative scoring models for survivin immunohistochemistry. Here, we present such a model. EXPERIMENTAL DESIGN: A breast cancer tissue microarray containing 102 tumors was stained with an anti-survivin antibody. Whole-slide scanning was used to capture high-resolution images. These images were analyzed using automated algorithms to quantify the staining. RESULTS: Increased nuclear, but not cytoplasmic, survivin was associated with a reduced overall survival (OS; P = 0.038) and disease-specific survival (P = 0.0015). A high cytoplasmic-to-nuclear ratio (CNR) of survivin was associated with improved OS (P = 0.005) and disease-specific survival (P = 0.05). Multivariate analysis revealed that the survivin CNR was an independent predictor of OS (hazard ratio, 0.09; 95% confidence interval, 0.01-0.76; P = 0.027). A survivin CNR of >5 correlated positively with estrogen receptor (P = 0.019) and progesterone receptor (P = 0.033) levels, whereas it was negatively associated with Ki-67 expression (P = 0.04), p53 status (P = 0.005), and c-myc amplification (P = 0.016). CONCLUSION: Different prognostic information is supplied by nuclear and cytoplasmic survivin in breast cancer. Nuclear survivin is a poor prognostic marker in breast cancer. Moreover, CNR of survivin, as determined by image analysis, is an independent prognostic factor.
PURPOSE: Survivin (BIRC5) is a promising tumor biomarker. Conflicting data exist on its prognostic effect in breast cancer. These data may at least be partly due to the manual interpretation of immunohistochemical staining, especially as survivin can be located in both the nucleus and cytoplasm. Quantitative determination of survivin expression using image analysis offers the opportunity to develop alternative scoring models for survivin immunohistochemistry. Here, we present such a model. EXPERIMENTAL DESIGN: A breast cancer tissue microarray containing 102 tumors was stained with an anti-survivin antibody. Whole-slide scanning was used to capture high-resolution images. These images were analyzed using automated algorithms to quantify the staining. RESULTS: Increased nuclear, but not cytoplasmic, survivin was associated with a reduced overall survival (OS; P = 0.038) and disease-specific survival (P = 0.0015). A high cytoplasmic-to-nuclear ratio (CNR) of survivin was associated with improved OS (P = 0.005) and disease-specific survival (P = 0.05). Multivariate analysis revealed that the survivin CNR was an independent predictor of OS (hazard ratio, 0.09; 95% confidence interval, 0.01-0.76; P = 0.027). A survivin CNR of >5 correlated positively with estrogen receptor (P = 0.019) and progesterone receptor (P = 0.033) levels, whereas it was negatively associated with Ki-67 expression (P = 0.04), p53 status (P = 0.005), and c-myc amplification (P = 0.016). CONCLUSION: Different prognostic information is supplied by nuclear and cytoplasmic survivin in breast cancer. Nuclear survivin is a poor prognostic marker in breast cancer. Moreover, CNR of survivin, as determined by image analysis, is an independent prognostic factor.
Authors: B M Ryan; G E Konecny; S Kahlert; H-J Wang; M Untch; G Meng; M D Pegram; K C Podratz; J Crown; D J Slamon; M J Duffy Journal: Ann Oncol Date: 2006-01-10 Impact factor: 32.976
Authors: Donal J Brennan; Catherine Kelly; Elton Rexhepaj; Peter A Dervan; Michael J Duffy; William M Gallagher Journal: Cancer Genomics Proteomics Date: 2007 May-Jun Impact factor: 4.069
Authors: Martin Lodén; Maria Stighall; Niels Hilmer Nielsen; Göran Roos; Stefan O Emdin; Hanna Ostlund; Göran Landberg Journal: Oncogene Date: 2002-07-11 Impact factor: 9.867
Authors: Lisa Rydén; Barbro Linderholm; Niels Hilmer Nielsen; Stefan Emdin; Per-Ebbe Jönsson; Göran Landberg Journal: Breast Cancer Res Treat Date: 2003-12 Impact factor: 4.872
Authors: S M Kennedy; L O'Driscoll; R Purcell; N Fitz-Simons; E W McDermott; A D Hill; N J O'Higgins; M Parkinson; R Linehan; M Clynes Journal: Br J Cancer Date: 2003-04-07 Impact factor: 7.640
Authors: D J Brennan; D P O'Connor; H Laursen; S F McGee; S McCarthy; R Zagozdzon; E Rexhepaj; A C Culhane; F M Martin; M J Duffy; G Landberg; L Ryden; S M Hewitt; M J Kuhar; R Bernards; R C Millikan; J P Crown; K Jirström; W M Gallagher Journal: Oncogene Date: 2011-12-05 Impact factor: 9.867
Authors: Terence K Lee; Saravana R K Murthy; Niamh X Cawley; Savita Dhanvantari; Stephen M Hewitt; Hong Lou; Tracy Lau; Stephanie Ma; Thanh Huynh; Robert A Wesley; Irene O Ng; Karel Pacak; Ronnie T Poon; Y Peng Loh Journal: J Clin Invest Date: 2011-03 Impact factor: 14.808
Authors: Lindsay J Collin; Deirdre P Cronin-Fenton; Thomas P Ahern; Kristina B Christensen; Per Damkier; Stephen Hamilton-Dutoit; Anders Kjaersgaard; Kristina L Lauridsen; Rami Yacoub; Peer Christiansen; Henrik Toft Sørensen; Timothy L Lash Journal: Acta Oncol Date: 2018-10-23 Impact factor: 4.089
Authors: Canan Akfirat; Xiaotun Zhang; Aviva Ventura; Dror Berel; Mary E Colangelo; Cindy K Miranti; Maryla Krajewska; John C Reed; Celestia S Higano; Lawrence D True; Robert L Vessella; Colm Morrissey; Beatrice S Knudsen Journal: J Pathol Date: 2013-07 Impact factor: 7.996
Authors: Elton Rexhepaj; Karin Jirstrom; Darran P O'Connor; Sallyann L O'Brien; Goran Landberg; Michael J Duffy; Donal J Brennan; William M Gallagher Journal: BMC Cancer Date: 2010-11-23 Impact factor: 4.430
Authors: Fiona Lanigan; Gabriela Gremel; Rowena Hughes; Donal J Brennan; Finian Martin; Karin Jirström; William M Gallagher Journal: Breast Cancer Res Date: 2010-08-03 Impact factor: 6.466
Authors: Maryla Krajewska; Layton H Smith; Juan Rong; Xianshu Huang; Marc L Hyer; Nikolajs Zeps; Barry Iacopetta; Steven P Linke; Allen H Olson; John C Reed; Stan Krajewski Journal: J Histochem Cytochem Date: 2009-03-16 Impact factor: 2.479